Physician profile
Angel Morrobel
NPI 1790730679
$6,857.79
in general payments reported to CMS, 2019-2025
27 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $466 · 2021: $404 · 2022: $275 · 2023: $975 · 2024: $2,496 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057 · Travel and Lodging: $717 · Education: $50.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.86 |
| Travel and Lodging | $716.80 |
| Education | $50.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,548.62 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $741.73 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $498.66 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $488.80 | 2019-2024 | Farxiga |
| Lundbeck LLC | $399.87 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $392.60 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.56 | 2019-2025 | Jardiance |
| Pfizer INC. | $369.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $340.31 | 2019-2025 | |
| Amgen INC. | $230.81 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $208.87 | 2021-2025 | |
| Novo Nordisk INC | $182.65 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $168.81 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $159.52 | 2024-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $143.68 | 2021-2023 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $116.73 | 2019-2023 | Xarelto |
| W. L. Gore & Associates, INC. | $96.01 | 2021 | |
| Medtronic Vascular, INC. | $81.99 | 2019 | |
| Amarin Pharma, INC. | $69.23 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.58 | 2019-2020 | |
| Abbott Laboratories | $36.72 | 2024 | Assurity |
| Actelion Pharmaceuticals US, INC. | $35.23 | 2019-2023 | Opsumit |
| Boston Scientific Corporation | $28.55 | 2020-2021 | |
| Gilead Sciences, INC. | $28.47 | 2019 | |
| Cardiva Medical, INC. | $23.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.72 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $18.21 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Morrobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.